Patents by Inventor Thomas Wolfel

Thomas Wolfel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Melanoma-associated MHC class I associated oligopeptides and the uses thereof
    Publication number: 20090104186
    Abstract: The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
    Type: Application
    Filed: August 31, 2006
    Publication date: April 23, 2009
    Inventors: Daniela Eberts, Martina Fatho, Volker Lennerz, Chris Schmidt, Pierre Van Der Bruggen, Catherine Wolfel, Thomas Wolfel
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals
    Publication number: 20020128200
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Application
    Filed: December 11, 2001
    Publication date: September 12, 2002
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • Precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 6001975
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1998
    Date of Patent: December 14, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5856091
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 10, 1995
    Date of Patent: January 5, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Pierre Coulie, Thierry Boon-Falleur, Etienne De Plaen
  • Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5854203
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: December 29, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5843687
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur
  • Isolated tyrosinase derived peptides and uses thereof
    Patent number: 5843688
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: December 1, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
    Patent number: 5837476
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: November 17, 1998
    Assignee: Ludwig Institute
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 5747271
    Abstract: The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: May 5, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5744316
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: April 28, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Vincent Brichard, Aline Van Pel, Thomas Wolfel, Thierry Boon-Falleur
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5530096
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: June 25, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5519117
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: May 21, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline V. Pel, Vincent Brichard, Thierry Boon-Falleur
  • Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
    Patent number: 5487974
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase-derived peptide having the amino acid sequence Met Leu Leu Ala Val Leu Tyr Cys Leu Leu. The invention further relates to the detection of these complexes on the surface of abnormal cells and, in particular, on the surface of melanoma cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: January 30, 1996
    Assignee: Ludwig Institute for Cancer-Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe